SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

SPY072

SYRE·Spyre Therapeutics, Inc.
NEUTRAL
Drug Impact Rating6/10
Trial phase
Phase 2
Time to market
SPY072 is in Phase 2 clinical development. Even if the PsA/axSpA data are positive, the earliest potential approval would likely be 2029 or later, assuming successful Phase 3 trials and regulatory review.
Why 6/10
The next hard catalyst for SPY072 is the topline data from the PsA and axSpA sub-studies of the SKYWAY Phase 2 basket trial, expected in Q4 2026 (within ~2 months). SPY072 is a secondary program behind Spyre's IBD pipeline, so even a binary readout scores a 6 rather than higher.
Actionable Insight NEUTRAL

The next catalyst for SPY072 is topline data from the psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY Phase 2 basket trial, expected in Q4 2026 (any day now). Positive data could partially rehabilitate the asset after the RA miss and support its development in rheumatic disease and as a component of the SPY772 combination for hidradenitis suppurativa. Weak data would further narrow SPY072's addressable opportunity and increase focus on the company's IBD pipeline (SPY001, SPY002, SPY003).

Price Chart

Loading chart...

Executive Summary

SPY072 is an extended half-life anti-TL1A antibody from Spyre Therapeutics (NASDAQ: SYRE) being evaluated in a Phase 2 basket trial (SKYWAY) for rheumatic diseases. In August 2026, the RA sub-study showed statistical significance on the primary endpoint (DAS28-CRP) but the magnitude of effect fell short of the company's internal bar for monotherapy development, causing the stock to drop ~12%. The company is now awaiting topline data from the PsA and axSpA sub-studies, expected in Q4 2026. SPY072 has a differentiated ~75-day half-life (3x longer than first-generation TL1A antibodies) and is also being developed as part of the SPY772 combination program for hidradenitis suppurativa. However, SPY072 is a secondary program behind Spyre's IBD pipeline (SPY001, SPY002, SPY003), which is the primary driver of the stock's valuation.

How It Works

SPY072 is an injectable antibody that blocks TL1A, a protein that drives inflammation and tissue scarring in autoimmune diseases. By neutralizing TL1A, SPY072 aims to reduce inflammation in conditions like rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. It is engineered with a longer half-life than earlier TL1A antibodies, which could allow patients to receive injections less frequently (every 3 to 6 months instead of every 2 to 4 weeks).

Trial Status

The SKYWAY Phase 2 basket trial (NCT07148414) is evaluating SPY072 in three rheumatic disease sub-studies: RA (results reported Aug 2026), PsA (topline expected Q4 2026), and axSpA (topline expected Q4 2026). A separate Phase 2 SKYLIGHT trial in hidradenitis suppurativa began enrollment in September 2026 with topline data expected late 2027 or early 2028. Phase 1 data (reported 2025) showed a ~75-day half-life and favorable safety.

The Two-Sided Case

▲ Bull Case4
SPY072 met its primary endpoint (DAS28-CRP) with statistical significance at Week 12 in the RA sub-study, demonstrating proof-of-mechanism for TL1A inhibition in rheumatic disease
Phase 1 data showed a ~75-day half-life, more than 3x longer than first-generation anti-TL1A antibodies, supporting potential quarterly or twice-yearly subcutaneous maintenance dosing
The SPY772 program combining SPY072 with a novel anti-IL-17A/F antibody opens a differentiated path in hidradenitis suppurativa, a large unmet-need market
Spyre has a strong cash position of ~$1.47B (pro forma, Sept 30, 2026) providing runway into H2 2029, and analyst consensus is Strong Buy with a mean price target of $122.53 (23.4% upside from $99.27)
▼ Bear Case4
RA sub-study missed internal efficacy bar for monotherapy prioritization, causing the stock to fall ~12% on Aug 25, 2026, and raising questions about SPY072's differentiation in rheumatic disease
The anti-TL1A competitive field is crowded: Merck (tulisokibart) has Phase 3 UC data, Roche and Sanofi/Teva (duvakitug) are in Phase 3, and first-generation assets already have a head start in IBD and potentially rheumatic disease
SPY072's RA data showed only nominal significance on some endpoints (ACR20 with high dose, ACR50 with low dose) rather than consistent dose-response across all measures, suggesting modest efficacy
The company raised $378M in an October 2026 public offering, diluting existing shareholders, to fund pipeline advancement including SPY072

Upcoming Catalysts

  • Topline data from SKYWAY PsA and axSpA sub-studies (Q4 2026)
  • SKYLIGHT Phase 2 HS trial topline Week 16 HiSCR75 data (late 2027 / early 2028)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Spyre Therapeutics, Inc. PRESS-RELEASE SYRE ·Originating report

Sources · 10

Hover a chip for the title
1 ir.spyre.com2 spyre.com3 fiercebiotech.com4 prnewswire.com5 markets.businessinsider.com6 biospace.com7 rttnews.com8 merck.com9 biospace.com10 sec.gov